PBAC to consider semaglutide listing for weight loss
The drug is still not marketed in Australia despite being registered last September.
Novo Nordisk has applied for PBS funding for its subcutaneous weight loss drug Wegovy as a severe obesity treatment.
The product contains the GLP-1 receptor agonist semaglutide — the same active ingredient as Ozempic — and was approved by the TGA in September last year for adults with obesity, or overweight in the presence of at least one weight-related comorbidity.
But Novo Nordisk has not marketed Wegovy in Australia and it remains unavailable.
The company’s PBAC application, which will be considered in November, requests a PBS listing “for the treatment of severe obesity despite prior participation in an appropriate lifestyle-based weight management intervention”.
